Close Menu

UCSF

The company is using a quantitative PCR method licensed from the University of Utah to measure telomere length from tissue samples for research, drug-development, and health-monitoring applications.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Under the terms of the deal, Myriad will have commercialization rights to "all tests derived from the technology on a worldwide basis in exchange for upfront fees and contingent payments based upon the commercial success of the products."

The partners aim to develop a transporter-based assay system capable of predicting absorption, distribution, metabolism, and excretion of drug candidates.

The team hopes the one-year grant will help it develop a quick, affordable assay that will be deployed in public health laboratories for disease surveillance. The lab is developing the assay to run on a portable instrument from Akonni Biosystems.

The researchers found that genetic ancestry could provide a better method of assessing potential lung function than current standard benchmarks, such as self-reported race or ethnicity.

At the Network Biology 2.0 conference, speakers underscored the degree to which the understanding of cancer is being empowered by molecular characterization projects and is accompanied by the desire to select the right populations for clinical trials.

The company's early access-program for its SmartChip system includes eight new university and corporate customers.

The early-access agreements provide Wafergen with an undisclosed amount of revenue, and are expected to help validate the SmartChip platform prior to its planned launch later this year.

UCSF will use Celera's KIF6 genetic variant discoveries to develop a test for cardiovascular risk and statin benefit.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.